Citadel Advisors’s BIO-REFERENCE LABS INC-NEW- BRLI Stock Holding History

Citadel Advisors’s Portfolio BRLI Stock Details BRLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-15,000	Closed	-$619K	–	9617
2015 Q2	$619K	Sell	15,000 -10,300	-41%	-$369K	﹤0.01%	4650
2015 Q1	$892K	Buy	25,300 +15,400	+156%	+$521K	﹤0.01%	4075
2014 Q4	$318K	Sell	9,900 -36,800	-79%	-$1.06M	﹤0.01%	5345
2014 Q3	$1.31M	Buy	46,700 +43,700	+1,457%	+$1.33M	﹤0.01%	3370
2014 Q2	$91K	Buy	+3,000	New	+$82.8K	﹤0.01%	6307

Other funds holding BRLI

SAM

Shell Asset Management The Hague, Netherlands $996M AUM 26.19% 1-Year Est. Return

Citadel Advisors's BRLI Position: Q3 2015 in Review

Citadel Advisors sold out of BIO-REFERENCE LABS INC-NEW- (BRLI) in Q3 2015, closing a stake of 9,357 shares — an estimated $386K sold.

Citadel Advisors first reported a position in BRLI in Q3 2013 and held it in 5 quarters. The position peaked at $746K in Q3 2014. 1 fund tracked by Wall St. Rank holds BRLI as of Q3 2015.

Citadel Advisors reported no remaining BIO-REFERENCE LABS INC-NEW- position as of Q3 2015 after selling out during the quarter.
Citadel Advisors sold 9,357 BIO-REFERENCE LABS INC-NEW- shares in Q3 2015, an estimated $386K.
Citadel Advisors first reported a position in BIO-REFERENCE LABS INC-NEW- in Q3 2013 and held it in 5 quarters.
Citadel Advisors's BIO-REFERENCE LABS INC-NEW- position peaked at $746K in Q3 2014.
1 fund tracked by Wall St. Rank held BIO-REFERENCE LABS INC-NEW- as of Q3 2015.

Based on Citadel Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.